阿奇霉素联合常规西药治疗社区获得性肺炎临床观察(1)

http://www.100md.com 2010年9月1日 杨蕴梅

第1页

    参见附件(1622KB，2页)。

     【摘要】 目的 对我院收治166例社区获得性肺炎患者应用阿奇霉素联合常规西药进行干预治疗,以探索阿奇霉治疗社区获得性肺炎的效果。 方法 对于确诊为社区获得性肺炎的患者,根据治疗方式的不同分为联合用药组(阿奇霉素联合常规西药治疗)和对照组(常规西药治疗),对比分析两组治疗的效果以及副作用的情况。 结果 联合用药组的显效率和总有效率均明显高于对照组西药常规治疗的效率,与之比较有显著差异(P<0.05)。联合用药组的体温恢复正常天数、体征恢复正常天数、理化指标恢复正常天数明显低于对照组的天数,与之比较均有显著差异(P<0.05)。各组的不良反应率统计学比较无显著差异(P>0.05)。 结论 阿奇霉素联合常规西药治疗社区获得性肺炎有一定优势。

    【关键词】社区获得性肺炎 阿奇霉素 临床疗效 不良反应

    中图分类号:R563文献标识号:A文章编号:1005-0515(2010)09-004-02

    【Abstract】 Objective The hospital treated 166 cases of community-acquired pneumonia patients with azithromycin combined treatment of conventional western medicine to intervene in order to explore the treatment-acquired pneumonia azithromycin results. Methods For the diagnosis of community-acquired pneumonia patients, according to the different treatments were divided into combined treatment group (azithromycin combined conventional western medicine) and the control group (conventional western medicine), Comparative analysis of two groups of treatment effects and side-effects. Results The combined treatment group the markedly effective rate and total effective

    rate was significantly higher than the efficiency of western conventional treatment, as compared were significantly different (P <0.05). The combination group of the body temperature returned to normal days, signs returned to normal the number of days, physical and chemical indicators of the number of days to resume normal control group was significantly lower than the number of days with them were significantly different (P <0.05). The adverse reaction rate of each group compared statistically no difference (P> 0.05). Conclusion Azithromycin combined conventional western medicine in treating community-acquired pneumonia has certain advantages.

    【Key words】 community-acquired pneumonia; Azithromycin; clinical effect;adverse reaction;

    社区获得性肺炎(community-acquired pneumonia,简称CAP)是指在医院外罹患的感染性肺实质(含肺泡壁即广义上的肺间质)炎症,包括具有明确潜伏期的病原体感染而在入院后平均潜伏期内发病的肺炎。当今抗生素时代,CAP仍然是威胁人群健康的重要疾病,特别是由于社会人口老龄化、免疫损害宿主增加、病原体变迁和抗生素耐药率上升,CAP的治疗面临许多新问题。阿奇霉素是一种属于大环内酯类的抗生素,特别适用于由肺炎衣原体、流感嗜血杆菌、嗜肺军团菌、卡他摩拉菌、金黄色葡萄球菌或肺炎链球菌引起的呼吸道疾病[1]。本文通过对我院使用阿奇霉素联合用药治疗CAP的病例的分析,以探索阿奇霉治疗CAP的最佳方法,具体报道如下。

    1资料与方法

    1.1一般资料

    选择2007年1月-2009年12月在我院确诊为社区获得性肺炎患者166例 ......

    http://www.100md.com/html/paper/1005-0515A/2010/09/03.htm

您现在查看是摘要介绍页，详见PDF附件(1622KB，2页)。